Leerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted its price target Boston Scientific (NYSE: BSX) price target of $21.00 (from $18.00) following Q1 results and solid 2015 outlook.

Antalffy commented, "Over the last two years, BSX's turnaround story has steadily played out, with new management delivering solid execution against both near- and long-term sales and EPS growth targets. Given the company’s recent consistency in delivering EPS in-line or better than expectations – now 10 consecutive quarters – and an upcoming slew of new product launches, we are increasingly confident that BSX is likely to raise its long-term growth targets at the upcoming analyst day on Friday, May 1st, in NYC. Currently, these long-term goals include: (1) Acceleration to mid-single-digit sales growth by 2016; (2) ~72% gross margin by 2017; and (3) ~25% operating margin (EBITA) by 2017. With 2 years of execution now behind us and BSX already at mid-single-digit sales growth and tracking well along the gross and operating margin targets, we believe the company is likely to raise these goals out through the 2019-2020 timeframe -- all with the ultimate goal of delivering consistent double-digit EPS growth for the foreseeable future."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $17.75 yesterday.